The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

The Cancer Drug Development Forum (CDDF) is delighted to announce that a white paper, “Empowering Effective Biomarker-Driven Precision Oncology: A Call to Action” has been published in European Journal of Cancer (Vol 209, September 2024).

This paper has been developed following the CDDF multi-stakeholder on The Critical Role of Biomarkers in Precision Oncology that took place in November 2023. The meeting generated insightful discussions among a group of diverse stakeholders, diving deep into key topics in the area.

🔶 Read the full article here: https://cddf.org/wp-content/uploads/2024/07/Empowering-effective-biomarker-driven-precision-oncology_2024.pdf

🔶Thank the following authors for their invaluable contributions:

Mark Lawler, Peter Keeling, Olga Kholmanskikh, Warnyta Minnaard, Heike Moehlig-Zuttermeister, Nicola Normanno, Reena Philip, Claudia Popp, Roberto Salgado, Ademi E. Santiago-Walker , Ana Trullas, Sahar B. van Waalwijk van Doorn-Khosrovani, Richard Vart, Jessica Vermeulen, Marianna Vitaloni, Jaap Verweij

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

info@cddf.org
Tel: +32 2 880 62 70